Androgen receptor‐mediated regulation of BRCA1 modulates the antioxidant defense in prostate cancer
The Journal of Pathology · 2025
DOI: 10.1002/path.6468 ↗At a glance
Journal article in The Journal of Pathology, 2025. Written by Saiganesh Sriraman and 8 co-authors. Institution: Cancer Research Unit, Institute of Biomedicine, and FICAN West Cancer Center Laboratory, University of Turku and Turku University Hospital, Turku, Fi…. Major MEDLINE topics: Receptors, Androgen, BRCA1 Protein, Prostatic Neoplasms, Antioxidants. Cited 4 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Opetushallitus, Instrumentariumin Tiedesäätiö, Suomen Lääketieteen Säätiö.
Abstract (original language)
Lethal prostate cancer (PCa) is a genetically heterogeneous disease characterized by evolving androgen receptor (AR) signaling, eventually culminating in castration resistance. The tumor suppressor gene BRCA1 has multiple functions that include secondary processes cooperating with its main function as a caretaker of genomic integrity. BRCA1 is often mutated in breast and ovarian cancer, but BRCA1 mutations are also associated with PCa, although they are less frequently observed. Most PCa patients do not, however, carry BRCA1 mutations, and interestingly, it has been shown that BRCA1 expression is enriched in castration‐resistant PCa. In this study we elucidated the prostate tissue‐specific role of the BRCA1 protein. Although the regulation of DNA damage response genes has been studied in PCa, comprehensive analyses of BRCA1 regulation in the context of androgen signaling are lacking. Our results indicate that BRCA1 is dynamically regulated by AR signaling and that activation of AR via its natural ligand, dihydrotestosterone, represses BRCA1 expression. Our analyses both in vitro and of patient samples and mouse xenografts showed that BRCA1 expression was induced and sustained after androgen deprivation. Moreover, we observed that oxidative stress–related pathways were regulated by BRCA1 in PCa cells and that androgen deprivation therapy–induced activation of BRCA1 supported the function of NRF2, the master regulator of antioxidant defense, and a known interactor of BRCA1. Impaired NRF2 activity, in the absence of BRCA1, decreased growth in a 3D environment. Our findings shed light on the functional role of BRCA1 protein in PCa and suggest that BRCA1 is regulated by the evolving AR signaling state during PCa progression. Thus, AR‐mediated suppression of BRCA1 accumulates oncogenic alterations in the early phases of PCa tumor progression and safeguards from excessive reactive oxygen species (ROS) when upregulated during androgen deprivation therapy. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Cancer Research Unit, Institute of Biomedicine, and FICAN West Cancer Center Laboratory, University of Turku and Turku University Hospital, Turku, Finland.
- InFLAMES Research Flagship Center, University of Turku and Åbo Akademi University, Turku, Finland.
- Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, and FICAN West Cancer Center, University of Turku, Turku, Finland.
- Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
- Department of Pathology, Tyks Laboratories, Turku University Hospital, Turku, Finland.
- Department of Oncology, Turku University Hospital, Turku, Finland.
ORCID profiles: Saiganesh Sriraman, Verneri Virtanen, Maria Sundvall
Funding
- Opetushallitus
- Instrumentariumin Tiedesäätiö
- Suomen Lääketieteen Säätiö
- Academy of Finland
- Lounais-Suomen Syöpäyhdistys
- Syöpäsäätiö
- Varsinais-Suomen Sairaanhoitopiiri
- Turun Yliopistosäätiö
Cite
APA
Sriraman, S., Virtanen, V., Kukkula, A., Toriseva, M., Lumiainen, A., West, G., Poutanen, M., Taimen, P., & Sundvall, M. (2025). Androgen receptor‐mediated regulation of BRCA1 modulates the antioxidant defense in prostate cancer. The Journal of Pathology. https://doi.org/10.1002/path.6468
Vancouver
Sriraman S, Virtanen V, Kukkula A, Toriseva M, Lumiainen A, West G, et al. Androgen receptor‐mediated regulation of BRCA1 modulates the antioxidant defense in prostate cancer. The Journal of Pathology. 2025. doi:10.1002/path.6468
BibTeX
@article{Sriraman2025,
author = {Sriraman, Saiganesh and Virtanen, Verneri and Kukkula, Antti and Toriseva, Mervi and Lumiainen, Anni and West, Gun and Poutanen, Matti and Taimen, Pekka and Sundvall, Maria},
title = {Androgen receptor‐mediated regulation of BRCA1 modulates the antioxidant defense in prostate cancer},
journal = {The Journal of Pathology},
year = {2025},
doi = {10.1002/path.6468}
}
EUVIMED